The Effects of Lovastatin on Primary Hypercholesterolemic Subjects

This study has done in subjects with primary hy-percholesterolemia with 25 female (65.8%) and 13 male (34.2). Subjets have taken 20 mg lovastatin with dinner during the six weeks. It reduced from 295 5 mgldL to 230±7 mgldL with cholesterol and 203±4 v.s. 150±6 mgldL with LDL-cholesterol and 243±15 v.s. 165 -±I2 mgldL with triglyceride and 48±19 v.s. 33±15 mgldL with VLDL- cholesterol after lovastatin therapy. These changes were found statistically highly signıficant (p<0.001). IIDL-cholesterol increased from the level of 45.9-±1.7 mgldL to the level of 50.2±1.8 mgldL af-ter treatmet. This difference was not statistically sig-nificant, but ERF and LDL-KIIIDL-K and HDL ratio changed statistically highly significant (p<0.001). There were no clinical or biochemical side effect related to this drug. It is in conclusion that 20 mg lovastatin is a safe, well-tolerated drug, which has been shown to lower LDL-cholesterol and total cholesterol level in subjetcs with primary hypercholesterolemia.